Scholarlink

<p>Reliable and minimally invasive analytical tools for monitoring molecular alterations associated with Parkinson’s disease (PD) remain limited. In this work, a nano-plasmonic sensing platform based on surface-enhanced Raman spectroscopy (SERS) using citrate-reduced silver nano-colloids is developed as a reproducible microanalytical method for serum fingerprinting of PD. The platform enables label-free detection of disease-associated biochemical and conformational changes by enhancing vibrational signatures at the nano-bio interface. Distinct Raman bands at 1138, 1190, and 1740&#xa0;cm<sup>−</sup>¹, together with systematic variations in the amide I region, reveal perturbations in protein-, lipid-, and metabolite-associated vibrational signatures, including changes in protein secondary structure and lipid dysregulation. Quantitative deconvolution analysis demonstrates a significant increase in the β-sheet/α-helix ratio with disease severity, providing a conformational spectral metric for monitoring neurodegenerative progression. Multivariate statistical analysis, including principal component analysis and linear discriminant analysis, confirms clear discrimination between diseased and control serum samples, highlighting the platform’s analytical capability to distinguish disease-associated biochemical signatures. Therapeutic intervention with <i>Mucuna pruriens</i> extract produces dose-dependent normalization of SERS spectral fingerprints, consistent with behavioural recovery, attenuation of oxidative stress, and reduced α-synuclein burden. A comparative analysis further indicates that serum yields more consistent and diagnostically robust SERS signatures than brain tissue, owing to lower spatial variability and clearer spectral markers. Overall, the proposed nano-plasmonic SERS strategy establishes a rapid, reproducible, and minimally invasive microanalytical approach for biochemical fingerprinting and therapeutic response monitoring in Parkinson’s disease, demonstrating its potential utility for analytical neurodiagnostics based on serum biomarkers.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nano-plasmonic SERS-based serum fingerprinting for analytical monitoring of Parkinson’s disease and therapeutic response

  • 期刊论文

  • 发表日期：

    2026年4月15日

查看全文
  • Monalisha Nayak,
  • Ashish Kumar Singh,
  • Ranjan Kumar Singh

摘要

Reliable and minimally invasive analytical tools for monitoring molecular alterations associated with Parkinson’s disease (PD) remain limited. In this work, a nano-plasmonic sensing platform based on surface-enhanced Raman spectroscopy (SERS) using citrate-reduced silver nano-colloids is developed as a reproducible microanalytical method for serum fingerprinting of PD. The platform enables label-free detection of disease-associated biochemical and conformational changes by enhancing vibrational signatures at the nano-bio interface. Distinct Raman bands at 1138, 1190, and 1740 cm−¹, together with systematic variations in the amide I region, reveal perturbations in protein-, lipid-, and metabolite-associated vibrational signatures, including changes in protein secondary structure and lipid dysregulation. Quantitative deconvolution analysis demonstrates a significant increase in the β-sheet/α-helix ratio with disease severity, providing a conformational spectral metric for monitoring neurodegenerative progression. Multivariate statistical analysis, including principal component analysis and linear discriminant analysis, confirms clear discrimination between diseased and control serum samples, highlighting the platform’s analytical capability to distinguish disease-associated biochemical signatures. Therapeutic intervention with Mucuna pruriens extract produces dose-dependent normalization of SERS spectral fingerprints, consistent with behavioural recovery, attenuation of oxidative stress, and reduced α-synuclein burden. A comparative analysis further indicates that serum yields more consistent and diagnostically robust SERS signatures than brain tissue, owing to lower spatial variability and clearer spectral markers. Overall, the proposed nano-plasmonic SERS strategy establishes a rapid, reproducible, and minimally invasive microanalytical approach for biochemical fingerprinting and therapeutic response monitoring in Parkinson’s disease, demonstrating its potential utility for analytical neurodiagnostics based on serum biomarkers.

Graphical Abstract